Diagnostic accuracy of a high-throughput multiplex immunoassay for the detection of Mpox virus infection and MVA-BN vaccination up to two years after exposure

Mpox, caused by mpox virus (MPXV), has gained global attention following the 2022 Clade IIb outbreak and the emergence of two novel Clade I lineages in 2023 and 2024. In this context, accurate and high-throughput detection of MPXV-specific antibodies has become essential for surveillance programs, diagnosis and vaccine trials. To address this need, we validated the long-term diagnostic accuracy of an mpox multiplex IgG immunoassay (called MpoxPlex) that measures IgG responses to 11 orthopoxvirus antigens. The MpoxPlex assay was validated in a Belgian cohort of mpox patients (n=226) and MVA-BN vaccine recipients (n=194), who were followed up for two years post-exposure. We used receiver operator characteristic (ROC) analysis to assess diagnostic performance at multiple time points post-infection or vaccination. To explore the assay’s broader utility, we also investigated correlations between antigen-specific IgG responses and neutralizing antibody titers. To further optimize antigen combinations, we applied a machine learning (random forest) algorithm. In individuals without prior smallpox vaccination, the MpoxPlex assay accurately detected mpox infection up to two years post-infection, achieving 82% sensitivity and 95% specificity when multiple antigens were combined. In contrast, diagnostic performance was low in previously smallpox or MVA-BN vaccinated individuals, with sensitivity dropping below 50% already after six months. Among MVA-BN–vaccinated individuals, IgG titers waned within one year. Most antigen-specific IgG responses correlated strongly with neutralizing antibody titers, supporting their relevance in immune monitoring. The MpoxPlex assay exhibits high sensitivity and specificity for detecting prior mpox infection in unvaccinated individuals, with reliable performance up to two years post-infection. This makes it well-suited for both retrospective diagnosis and large-scale serosurveillance. Its strong concordance with neutralizing antibody titers further supports its potential for monitoring long-term vaccine-induced immunity. However, antibody levels following MVA-BN vaccination waned within one year, and prior vaccination status should be carefully considered when interpreting results.